PriceTargets.com logo

Atara Biotherapeutics - ATRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $185.50
  • Forecasted Upside: 1,808.44%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.72 As of 09/13/2024 01:00 AM ET
▲ +1.64 (20.30%)

This chart shows the closing price for ATRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atara Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRA

Analyst Price Target is $185.50
▲ +1,808.44% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $185.50, with a high forecast of $700.00 and a low forecast of $11.00. The average price target represents a 1,808.44% upside from the last price of $9.72.

This chart shows the closing price for ATRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Atara Biotherapeutics. This rating has held steady since January 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
3/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
6/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/21/2024HC WainwrightReiterated RatingNeutralLow
8/16/2024MizuhoUpgradeNeutral ➝ Outperform$25.00 ➝ $18.00Low
8/13/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00Low
7/17/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$12.50 ➝ $11.00Low
5/22/2024HC WainwrightReiterated RatingNeutralLow
11/9/2023Evercore ISIDowngradeOutperform ➝ In-LineLow
11/9/2023HC WainwrightDowngradeBuy ➝ NeutralLow
11/9/2023MizuhoDowngradeBuy ➝ NeutralLow
9/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$700.00Low
6/14/2023HC WainwrightReiterated RatingBuy$675.00 ➝ $700.00Low
2/9/2023EF Hutton Acquisition Co. IReiterated RatingBuy$625.00Low
2/9/2023HC WainwrightLower TargetBuy$725.00 ➝ $675.00Low
2/7/2023MizuhoReiterated RatingBuy$775.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$625.00Low
8/16/2022MizuhoLower TargetBuy$975.00 ➝ $775.00Low
8/9/2022The Goldman Sachs GroupLower TargetSell$100.00 ➝ $75.00Low
7/20/2022CitigroupDowngradeNeutral ➝ Sell$200.00 ➝ $75.00Low
7/13/2022Canaccord Genuity GroupLower Target$1,675.00 ➝ $1,250.00Low
7/13/2022Stifel NicolausDowngradeBuy ➝ Hold$400.00 ➝ $125.00N/A
7/13/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$250.00N/A
5/24/2022The Goldman Sachs GroupLower TargetSell$125.00 ➝ $100.00Low
5/23/2022HC WainwrightLower TargetBuy$775.00 ➝ $725.00High
5/9/2022CitigroupDowngradeBuy ➝ Neutral$375.00 ➝ $200.00High
3/28/2022JPMorgan Chase & Co.Lower TargetOverweight$675.00 ➝ $550.00Low
3/1/2022Canaccord Genuity GroupLower Target$1,950.00 ➝ $1,675.00High
1/27/2022HC WainwrightReiterated RatingBuy$775.00High
1/14/2022HC WainwrightReiterated RatingBuy$775.00High
1/3/2022JPMorgan Chase & Co.Boost TargetOverweight$650.00 ➝ $675.00High
10/13/2021MizuhoInitiated CoverageBuy$1,025.00High
10/5/2021HC WainwrightReiterated RatingBuy$775.00Low
10/4/2021Stifel NicolausLower TargetBuy$750.00 ➝ $675.00Low
9/29/2021MizuhoInitiated CoverageBuy$1,025.00High
9/28/2021HC WainwrightReiterated RatingBuy$775.00High
5/13/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$575.00 ➝ $725.00Low
5/5/2021HC WainwrightLower TargetBuy$800.00 ➝ $775.00High
3/2/2021William BlairReiterated RatingOutperformLow
3/2/2021CitigroupUpgradeNeutral ➝ Buy$675.00High
12/9/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$500.00 ➝ $675.00High
12/8/2020HC WainwrightReiterated RatingBuy$700.00 ➝ $775.00Medium
12/7/2020Stifel NicolausBoost TargetBuy$700.00 ➝ $825.00Medium
11/23/2020MizuhoBoost TargetBuy$950.00 ➝ $1,025.00Low
11/13/2020Smith Barney CitigroupBoost Target$350.00 ➝ $500.00Low
11/10/2020HC WainwrightBoost TargetBuy$650.00 ➝ $700.00High
9/24/2020William BlairReiterated RatingBuyHigh
8/6/2020Stifel NicolausLower TargetBuy$750.00 ➝ $700.00Low
8/6/2020HC WainwrightBoost TargetBuy$625.00 ➝ $650.00High
6/30/2020Evercore ISIInitiated CoverageOutperformMedium
6/15/2020HC WainwrightInitiated CoverageBuy$625.00High
5/26/2020MizuhoInitiated CoverageBuy$950.00High
5/19/2020MizuhoInitiated CoverageBuy$950.00High
5/12/2020JPMorgan Chase & Co.Boost TargetNeutral$550.00 ➝ $575.00High
4/23/2020CitigroupUpgradeNeutral ➝ Buy$350.00High
12/10/2019CowenReiterated RatingBuyMedium
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$1,075.00 ➝ $550.00Low
10/25/2019Stifel NicolausReiterated RatingBuyLow
9/27/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$350.00 ➝ $225.00Medium
9/18/2019MizuhoSet TargetBuy$1,075.00Low
9/16/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$800.00 ➝ $375.00Medium
(Data available from 9/14/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/17/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/17/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/16/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $9.72
Low: $8.11
High: $9.81

50 Day Range

MA: $8.71
Low: $6.81
High: $12.27

52 Week Range

Now: $9.72
Low: $4.96
High: $49.00

Volume

195,636 shs

Average Volume

105,526 shs

Market Capitalization

$47.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Atara Biotherapeutics?

The following equities research analysts have issued reports on Atara Biotherapeutics in the last twelve months: Canaccord Genuity Group Inc., Evercore ISI, HC Wainwright, Mizuho, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ATRA.

What is the current price target for Atara Biotherapeutics?

4 Wall Street analysts have set twelve-month price targets for Atara Biotherapeutics in the last year. Their average twelve-month price target is $185.50, suggesting a possible upside of 1,808.4%. HC Wainwright has the highest price target set, predicting ATRA will reach $700.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for Atara Biotherapeutics in the next year.
View the latest price targets for ATRA.

What is the current consensus analyst rating for Atara Biotherapeutics?

Atara Biotherapeutics currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATRA, but not buy more shares or sell existing shares.
View the latest ratings for ATRA.

What other companies compete with Atara Biotherapeutics?

Other companies that are similar to Atara Biotherapeutics include Cortexyme, AlloVir, BioVie, Generation Bio and Vaxart. Learn More about companies similar to Atara Biotherapeutics.

How do I contact Atara Biotherapeutics' investor relations team?

Atara Biotherapeutics' physical mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (805) 623-4211 and its investor relations email address is [email protected]. The official website for Atara Biotherapeutics is www.atarabio.com. Learn More about contacing Atara Biotherapeutics investor relations.